Raman-based imaging can help clinicians identify tumor-containing tissue during surgery, but it is not a general cancer screening test and has not been shown by the evidence here to improve survival. The practical promise is faster tissue feedback: a molecular signal can reveal differences that may be hard to judge by appearance alone.
What Raman imaging detects
Raman spectroscopy measures light scattered by molecular vibrations. The resulting signal acts as a chemical fingerprint; because tumor and non-tumor tissue can differ in biochemical composition, software can use those differences to classify tissue. “Label-free” means the measurement does not rely on adding an external dye or contrast agent.
As an Amazon Associate I earn from qualifying purchases.
Not every Raman system makes an image in the same way. Point-probe spontaneous Raman spectroscopy samples tissue at a measurement spot. Stimulated Raman histology (SRH) uses stimulated Raman signals to create microscopy images of fresh tissue. SRH imaging of a removed specimen is distinct from taking in-situ measurements directly in a patient during surgery.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →What has been demonstrated in people?
In-situ brain tumor measurements
A 2024 multicenter study evaluated the Sentry Raman system during open brain tumor surgery in 67 adults, collecting 976 in-situ measurements. The investigators reported classification accuracy of 91% for glioblastoma, 97% for brain metastases and 96% for meningiomas. These are results for the tumor types and study conditions reported, not a guarantee of performance in other hospitals, cancers or clinical settings. Read the study in Scientific Reports.
#1 Best Overall
Those measurements support the feasibility of using Raman signals to help classify selected brain tumors during surgery. They do not establish performance as a screening test for people without symptoms, nor do they show that using the system changes treatment decisions or improves patient outcomes.
A multimodal study across several cancers
A 2017 study reported 97% accuracy, 100% sensitivity and 93% specificity for a system tested on brain, lung, colon and skin cancer specimens. Those figures belong to a combined instrument using Raman spectroscopy, intrinsic fluorescence and diffuse reflectance—not Raman alone. The study also reported eight seconds of total imaging time for its particular multimodal system; that is not a general scan time for Raman imaging. Read the study in Cancer Research.
Rank #2
Accuracy, sensitivity and specificity describe different things: accuracy is the share of classifications that are correct overall; sensitivity concerns detection of cases that have the condition; specificity concerns correctly identifying cases that do not. Their meaning depends on the study cohort and how the system was evaluated, so figures from one study should not be transferred to a different population or purpose.
How SRH is being translated into clinical workflows
Invenio Imaging markets its NIO Laser Imaging System for SRH of fresh tissue. The company says the workflow does not require staining or sectioning and that images can be generated in three minutes or less. That timing and workflow description are manufacturer claims, not a benchmark that applies to every Raman device. See Invenio’s NIO product information.
Invenio states that its Glioma Reveal image-analysis module is available for clinical use in the EU and is “For Research Use Only” in the United States, not for diagnostic procedures. This is the company’s stated regional status; intended use and availability are specific to the product and jurisdiction and can change. Invenio also lists an FDA Breakthrough Device Designation for a separate AI module intended to assist evaluation of bronchoscopic lung biopsies. Breakthrough designation is not FDA clearance or approval. See the company’s press information.
In 2021, Invenio announced CE marking for NIO under the then-applicable In Vitro Diagnostic Directive. That historical announcement does not by itself establish the system’s present regulatory status under current European rules. A regulator’s decision is tied to a particular device and intended use: research-only status, a designation, CE marking and marketing authorization are not interchangeable terms.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Where Raman imaging fits—and where it does not
The strongest near-term use described by the human evidence is tissue assessment around an operation: helping clinicians characterize a specimen or tissue in the surgical setting. Brain tumor classification, biopsy assessment and tumor-margin evaluation are related applications, but they are not the same indication or workflow.
Free tools Windows power users keep installed
One-click scans. No signup required.
- It is not established here as population screening. Results from surgical cohorts do not show how a system performs in asymptomatic people or across a general population.
- Classification is not the same as clinical benefit. A high accuracy figure does not, by itself, prove that clinicians make better decisions or that patients have better outcomes.
- Evidence is system- and setting-specific. Tumor type, measurement approach, study design, reference diagnosis and evaluation cohort all affect what a reported result means.
- Translation remains product- and region-specific. A vendor’s stated clinical availability or research-only labeling should not be generalized to other devices or countries.
Reviews describe continuing work on label-free optical methods for tumor-margin assessment and endoscopic cancer imaging, including efforts to improve clinical translation and miniaturize systems. They describe an active field, not proof that Raman imaging is routinely adopted or that it improves outcomes. Read the Annual Reviews discussion of label-free optical technologies.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
